Results 31 to 40 of about 15,553 (191)

Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. [PDF]

PLoS ONE, 2015
β-Lactamase inhibition is an important clinical strategy in overcoming β-lactamase-mediated resistance to β-lactam antibiotics in Gram negative bacteria.
Nikhil P Krishnan, Nhu Q Nguyen, Krisztina M Papp-Wallace, Robert A Bonomo, Focco van den Akker   +4 more
doaj   +1 more source

Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-2016 [PDF]

, 2017
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use.
Doumith, Michel, Hill, Robert, Hopkins, Katie L, Livermore, David M, Meunier, Danièle, Pike, Rachel, Staves, Peter, Woodford, Neil   +7 more
core   +1 more source

AmpC β-lactamase induction by avibactam and relebactam [PDF]

, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota, Livermore, David M, Mushtaq, Shazad, Nichols, Wright W, Woodford, Neil, Young, Katherine   +5 more
core   +1 more source

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia [PDF]

, 2017
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus ...
Chen, Q., Chow, J.W., Kim, M.J., Laud, P.J., Nguyen, D.A., Qin, X., Song, J., Stone, G.G., Tran, B.G., Wang, L.   +9 more
core   +1 more source

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016–2020

Antibiotics, 2023
Increasing antimicrobial resistance among multidrug-resistant (MDR), extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales (CPE), in particular metallo-β-lactamase (MBL)-positive strains, has led to limited treatment options ...
Denis Piérard, Elizabeth D. Hermsen, Michal Kantecki, Francis F. Arhin   +3 more
doaj   +1 more source

The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]

, 2018
The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core   +1 more source

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA) [PDF]

, 2016
Intra-abdominal infections (IAI) are an important cause of morbidity and are frequently associated with poor prognosis, particularly in high-risk patients.
A, A, A, A, A, A, A, A, A, A, A, A, A, AA, AC, AH, AJ, AK, AK, AM, AW, B, B, B, B, BJ, C, C, C, C, CA, CA, CE, D, D, D, DG, DP, E, EA, EE, F, F, F, F, FA, FM, FM, G, G, G, G, G, G, G, GA, GP, H, H, H, H, HAS, HE, I, I, I, I, IJ, J, J, JA, JE, JF, JG, JJ, JJ, JL, JR, JR, JR, JV, K, K, K, K, KA, KC, KYY, L, LJ, M, M, M, M, M, M, M, M, M, M, M, M, M, MA, MA, MA, MA, MC, MG, MM, MN, MP, N, N, NT, O, OR, P, P, P, P, PF, PK, R, R, R, R, R, R, R, RB, RG, RM, RR, RR, RS, RV, S, S, S, S, S, S, S, S, S, Sartelli, SJ, SK, SK, SM, SR, SR, SY, T, T, TL, TM, V, V, VG, VN, W, W, W, WL, WR, Y, YF, YH, YR, YS, Z, ZJ   +173 more
core   +7 more sources

In Vitro Activity Comparison of Ceftazidime–Avibactam and Aztreonam–Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China

Frontiers in Cellular and Infection Microbiology, 2021
ObjectivesThe aim of this work was to investigate the activity of ceftazidime–avibactam (CZA) and aztreonam–avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs).MethodsNon-duplicate CROs, including 56 carbapenem ...
Wei Yu, Luying Xiong, Qixia Luo, Yunbo Chen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao   +7 more
doaj   +1 more source

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria [PDF]

, 2017
Background: Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent ‘enhancer' effect, potentiating β-lactams targeting PBP3.
Livermore, David M, Mushtaq, Shazad, Vickers, Anna, Warner, Marina, Woodford, Neil   +4 more
core   +1 more source

identifying allosteric networks to fight antibiotics resistance [PDF]

, 2018
The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza, Barnes, Melissa D., Bonomo, Robert A., Galdadas, Ioannis, Gervasio, Francesco L., Haider, Shozeb, Healy, Jess, Lovera, Silvia, Pérez-Hernández, Guillermo, Woodford, Neil   +9 more
core   +1 more source